Evidence map›Paper›PMID 40279026›Full record

Observational studyInfection2025

Model-informed identification of optimised dosing strategies for meropenem in critically ill patients receiving SLEDD: an observational study.

Franz Weber, Christina Scharf, Linda B S Aulin, Ferdinand Weinelt, Michael Paal, Gerd Mikus, Michael Vogeser, Katharina Habler, Wilhelm Huisinga, Michael Zoller and 3 more

Registry-linked trialAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Infection, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03985605 (Therapeutic Drug Monitoring of Antiinfectives for Patients With Severe Illness), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03985605 completednot on this map

Therapeutic Drug Monitoring of Antiinfectives for Patients With Severe Illness

TypeobservationalSponsorLudwig-Maximilians - University of MunichRan2018 to 2022Enrolled500ConditionsInfection, Bacterial
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Franz Weber *Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universität Berlin, Kelchstraße 31, 12169, Berlin, Germany.
Christina Scharf *Department of Anaesthesiology, University Hospital, LMU Munich, Munich, Germany.
Linda B S AulinDepartment of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universität Berlin, Kelchstraße 31, 12169, Berlin, Germany.
Ferdinand WeineltDepartment of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universität Berlin, Kelchstraße 31, 12169, Berlin, Germany.
Michael PaalInstitute of Laboratory Medicine, University Hospital, LMU Munich, Munich, Germany.
Gerd MikusDepartment of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universität Berlin, Kelchstraße 31, 12169, Berlin, Germany.
Michael VogeserInstitute of Laboratory Medicine, University Hospital, LMU Munich, Munich, Germany.
Katharina HablerInstitute of Laboratory Medicine, University Hospital, LMU Munich, Munich, Germany.
Wilhelm HuisingaInstitute of Mathematics, University of Potsdam, Potsdam, Germany.
Michael ZollerDepartment of Anaesthesiology, University Hospital, LMU Munich, Munich, Germany.
Robin MicheletDepartment of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universität Berlin, Kelchstraße 31, 12169, Berlin, Germany.
Charlotte Kloft *Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universität Berlin, Kelchstraße 31, 12169, Berlin, Germany. charlotte.kloft@fu-berlin.de.
Uwe Liebchen *Department of Anaesthesiology, University Hospital, LMU Munich, Munich, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeAn increasing number of critically ill patients receive slow extended daily dialysis (SLEDD) due to their pathophysiology while suffering from sepsis, necessitating effective and safe antibiotic therapy. Although SLEDD reduces meropenem exposure and increases treatment failure risk, effective and safe dosing regimens are unclear. We aimed to identify optimised meropenem dosing strategies for critically ill SLEDD patients through population pharmacokinetic (PK) modelling and PK/pharmacodynamic (PD)-based probability of target attainment (PTA) analysis.

methodsClinical data from a prospective study involving critically ill SLEDD patients receiving meropenem were monitored through routine therapeutic drug monitoring. A total of 178 blood samples from 13 patients (median 14 samples per patient) were analysed. A PK model was developed and utilised to evaluate 24 clinically relevant dosing regimens during SLEDD therapy (7-h on-SLEDD periods q24h) in PTA analyses. The PK/PD target window of minimum meropenem concentration between 8 mg/L (P. aeruginosa; R-breakpoint) and 44.45 mg/L (toxicity threshold) was used.

resultsA one-compartment PK model with linear elimination and total clearance (CL) split into renal (CL

conclusionOur easy-to-use dosing nomogram presents a promising tool in optimising meropenem dosing regimens for critically ill SLEDD patients considering their kidney function in clinical practice.

trial registrationClinicaltrials.gov NCT03985605. Registered 14 June 2019. https://classic. CLINICALTRIALS: gov/ct2/show/study/NCT03985605.

Indexed as

Anti-Bacterial AgentsCritical IllnessMeropenemRenal DialysisAdultAgedAged, 80 and overDrug MonitoringFemaleHumansMaleMiddle AgedProspective StudiesSepsisAnti-Bacterial AgentsMeropenemClinical PK/PD target attainmentCritically illMeropenemPharmacokineticsSLEDD

Identifiers

PMID40279026
PMCPMC12460387

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.